The human cathelicidin antimicrobial peptide LL-37 as a potential treatment for polymicrobial infected wounds.
Diabetic patients often have ulcers on their lower-limbs that are infected by multiple biofilm-forming genera of bacteria, and the elimination of the biofilm has proven highly successful in resolving such wounds in patients. To that end, antimicrobial peptides have shown potential as a new anti-biof...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2013-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fimmu.2013.00143/full |
| _version_ | 1819139264547389440 |
|---|---|
| author | Allen J Duplantier Monique L. van Hoek |
| author_facet | Allen J Duplantier Monique L. van Hoek |
| author_sort | Allen J Duplantier |
| collection | DOAJ |
| description | Diabetic patients often have ulcers on their lower-limbs that are infected by multiple biofilm-forming genera of bacteria, and the elimination of the biofilm has proven highly successful in resolving such wounds in patients. To that end, antimicrobial peptides have shown potential as a new anti-biofilm approach. The single human cathelicidin peptide LL-37 has been shown to have antimicrobial and antibiofilm activity against multiple gram-positive and gram-negative human pathogens, and have wound-healing effects on the host. The combination of the anti-biofilm effect and wound-healing properties of LL-37 may make it highly effective in resolving polymicrobially infected wounds when topically applied. Such a peptide or its derivatives could be a platform from which to develop new therapeutic strategies to treat biofilm-mediated infections of wounds. This review summarizes known mechanisms that regulate the endogenous levels of LL-37 and discusses the antibiofilm, antibacterial and immunological effects of deficient versus excessive concentrations of LL-37 within the wound environment. Here, we review recent advances in understanding the therapeutic potential of this peptide and other clinically advanced peptides as a potential topical treatment for polymicrobial infected wounds. |
| first_indexed | 2024-12-22T11:19:54Z |
| format | Article |
| id | doaj.art-6bc10a7f0680452c94412261d875efe9 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-22T11:19:54Z |
| publishDate | 2013-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-6bc10a7f0680452c94412261d875efe92022-12-21T18:27:54ZengFrontiers Media S.A.Frontiers in Immunology1664-32242013-07-01410.3389/fimmu.2013.0014346550The human cathelicidin antimicrobial peptide LL-37 as a potential treatment for polymicrobial infected wounds.Allen J Duplantier0Monique L. van Hoek1George Mason UniversityGeorge Mason UniversityDiabetic patients often have ulcers on their lower-limbs that are infected by multiple biofilm-forming genera of bacteria, and the elimination of the biofilm has proven highly successful in resolving such wounds in patients. To that end, antimicrobial peptides have shown potential as a new anti-biofilm approach. The single human cathelicidin peptide LL-37 has been shown to have antimicrobial and antibiofilm activity against multiple gram-positive and gram-negative human pathogens, and have wound-healing effects on the host. The combination of the anti-biofilm effect and wound-healing properties of LL-37 may make it highly effective in resolving polymicrobially infected wounds when topically applied. Such a peptide or its derivatives could be a platform from which to develop new therapeutic strategies to treat biofilm-mediated infections of wounds. This review summarizes known mechanisms that regulate the endogenous levels of LL-37 and discusses the antibiofilm, antibacterial and immunological effects of deficient versus excessive concentrations of LL-37 within the wound environment. Here, we review recent advances in understanding the therapeutic potential of this peptide and other clinically advanced peptides as a potential topical treatment for polymicrobial infected wounds.http://journal.frontiersin.org/Journal/10.3389/fimmu.2013.00143/fullAntimicrobial peptideBiofilmchronic woundsinfected woundscathelicidin. |
| spellingShingle | Allen J Duplantier Monique L. van Hoek The human cathelicidin antimicrobial peptide LL-37 as a potential treatment for polymicrobial infected wounds. Frontiers in Immunology Antimicrobial peptide Biofilm chronic wounds infected wounds cathelicidin. |
| title | The human cathelicidin antimicrobial peptide LL-37 as a potential treatment for polymicrobial infected wounds. |
| title_full | The human cathelicidin antimicrobial peptide LL-37 as a potential treatment for polymicrobial infected wounds. |
| title_fullStr | The human cathelicidin antimicrobial peptide LL-37 as a potential treatment for polymicrobial infected wounds. |
| title_full_unstemmed | The human cathelicidin antimicrobial peptide LL-37 as a potential treatment for polymicrobial infected wounds. |
| title_short | The human cathelicidin antimicrobial peptide LL-37 as a potential treatment for polymicrobial infected wounds. |
| title_sort | human cathelicidin antimicrobial peptide ll 37 as a potential treatment for polymicrobial infected wounds |
| topic | Antimicrobial peptide Biofilm chronic wounds infected wounds cathelicidin. |
| url | http://journal.frontiersin.org/Journal/10.3389/fimmu.2013.00143/full |
| work_keys_str_mv | AT allenjduplantier thehumancathelicidinantimicrobialpeptidell37asapotentialtreatmentforpolymicrobialinfectedwounds AT moniquelvanhoek thehumancathelicidinantimicrobialpeptidell37asapotentialtreatmentforpolymicrobialinfectedwounds AT allenjduplantier humancathelicidinantimicrobialpeptidell37asapotentialtreatmentforpolymicrobialinfectedwounds AT moniquelvanhoek humancathelicidinantimicrobialpeptidell37asapotentialtreatmentforpolymicrobialinfectedwounds |